PDE5A and pulmonary arterial hypertension: Therefore, a PDE5 inhibitor developed in Brazil, lodenafil [9], has shown promising results regarding PAH treatment [10] because of its comparable efficacy to sildenafil in preclinical studies on reverting PAH [11].